Lotus Pharmaceuticals (路坦制药有限公司) said the SFDA indicated it would grant fast-track approval to begin clinical trials of its asthma drug Laevo-Bambutero. At a meeting held as part of its Investigative New Drug Application, Lotus was told the Beijing office of the SFDA would issue the approval to begin clinical trials. More details...

Stock Symbol: (OTCBB: LTUS)